Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Dec. 31, 2015 | Jan. 31, 2016 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Dec. 31, 2015 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | VIVO | |
Entity Registrant Name | MERIDIAN BIOSCIENCE INC | |
Entity Central Index Key | 794,172 | |
Current Fiscal Year End Date | --09-30 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 42,051,142 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Income Statement [Abstract] | ||
NET REVENUES | $ 47,160 | $ 48,013 |
COST OF SALES | 15,577 | 18,776 |
GROSS PROFIT | 31,583 | 29,237 |
OPERATING EXPENSES | ||
Research and development | 3,381 | 3,103 |
Selling and marketing | 6,443 | 6,080 |
General and administrative | 8,173 | 7,385 |
Total operating expenses | 17,997 | 16,568 |
OPERATING INCOME | 13,586 | 12,669 |
OTHER INCOME (EXPENSE) | ||
Interest income | 17 | 6 |
Other, net | 96 | (582) |
Total other income (expense) | 113 | (576) |
EARNINGS BEFORE INCOME TAXES | 13,699 | 12,093 |
INCOME TAX PROVISION | 4,806 | 4,192 |
NET EARNINGS | $ 8,893 | $ 7,901 |
BASIC EARNINGS PER COMMON SHARE | $ 0.21 | $ 0.19 |
DILUTED EARNINGS PER COMMON SHARE | $ 0.21 | $ 0.19 |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC | 41,947 | 41,607 |
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS | 380 | 334 |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-DILUTED | 42,327 | 41,941 |
ANTI-DILUTIVE SECURITIES: | ||
Common share options and restricted shares and units | 450 | 566 |
DIVIDENDS DECLARED PER COMMON SHARE | $ 0.20 | $ 0.20 |
Condensed Consolidated Stateme3
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Statement of Comprehensive Income [Abstract] | ||
Net earnings | $ 8,893 | $ 7,901 |
Foreign currency translation adjustment | (787) | (1,365) |
COMPREHENSIVE INCOME | $ 8,106 | $ 6,536 |
Condensed Consolidated Stateme4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net earnings | $ 8,893 | $ 7,901 |
Non-cash items included in net earnings: | ||
Depreciation of property, plant and equipment | 896 | 927 |
Amortization of intangible assets | 388 | 469 |
Amortization of deferred illumigene® instrument costs | 281 | 395 |
Stock-based compensation | 1,611 | 1,428 |
Deferred income taxes | 433 | 100 |
Change in current assets | (1,186) | 4,878 |
Change in current liabilities | 834 | 246 |
Other, net | (58) | (259) |
Net cash provided by operating activities | 12,092 | 16,085 |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Purchases of property, plant and equipment | (776) | (1,331) |
Purchase of equity method investment | (600) | |
Purchases of intangible assets | (16) | |
Net cash used for investing activities | (1,392) | (1,331) |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Dividends paid | (8,407) | (8,330) |
Proceeds and tax benefits from exercises of stock options | 1,470 | 499 |
Net cash used for financing activities | (6,937) | (7,831) |
Effect of Exchange Rate Changes on Cash and Equivalents | (314) | (454) |
Net Increase in Cash and Equivalents | 3,449 | 6,469 |
Cash and Equivalents at Beginning of Period | 49,973 | 43,047 |
Cash and Equivalents at End of Period | $ 53,422 | $ 49,516 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2015 | Sep. 30, 2015 |
CURRENT ASSETS | ||
Cash and equivalents | $ 53,422 | $ 49,973 |
Accounts receivable, less allowances of $222 and $248 | 27,617 | 26,254 |
Inventories | 38,778 | 35,817 |
Prepaid expenses and other current assets | 3,414 | 7,378 |
Total current assets | 123,231 | 119,422 |
PROPERTY, PLANT AND EQUIPMENT, at Cost | ||
Land | 981 | 986 |
Buildings and improvements | 30,119 | 30,056 |
Machinery, equipment and furniture | 42,363 | 41,541 |
Construction in progress | 938 | 1,139 |
Subtotal | 74,401 | 73,722 |
Less: accumulated depreciation and amortization | 46,952 | 46,230 |
Net property, plant and equipment | 27,449 | 27,492 |
OTHER ASSETS | ||
Goodwill | 22,064 | 22,349 |
Other intangible assets, net | 5,465 | 5,931 |
Restricted cash | 1,000 | 1,000 |
Deferred illumigene instrument costs, net | 1,671 | 1,750 |
Deferred income taxes | 4,566 | 4,954 |
Other assets | 989 | 384 |
Total other assets | 35,755 | 36,368 |
TOTAL ASSETS | 186,435 | 183,282 |
CURRENT LIABILITIES | ||
Accounts payable | 7,208 | 6,646 |
Accrued employee compensation costs | 4,990 | 5,132 |
Other accrued expenses | 2,601 | 2,587 |
Income taxes payable | 933 | 886 |
Total current liabilities | 15,732 | 15,251 |
NON-CURRENT LIABILITIES | $ 2,129 | $ 2,158 |
COMMITMENTS AND CONTINGENCIES | ||
SHAREHOLDERS' EQUITY | ||
Preferred stock, no par value; 1,000,000 shares authorized; none issued | ||
Common shares, no par value; 71,000,000 shares authorized; 42,044,388 and 41,838,399 shares issued, respectively | $ 0 | $ 0 |
Additional paid-in capital | 120,153 | 117,151 |
Retained earnings | 51,538 | 51,052 |
Accumulated other comprehensive income (loss) | (3,117) | (2,330) |
Total shareholders' equity | 168,574 | 165,873 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 186,435 | $ 183,282 |
Condensed Consolidated Balance6
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2015 | Sep. 30, 2015 |
Statement of Financial Position [Abstract] | ||
Allowances for accounts receivable | $ 222 | $ 248 |
Preferred stock, par value | ||
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Common stock, par value | ||
Common stock, shares authorized | 71,000,000 | 71,000,000 |
Common stock, shares issued | 42,044,388 | 41,838,399 |
Condensed Consolidated Stateme7
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - 3 months ended Dec. 31, 2015 - USD ($) shares in Thousands, $ in Thousands | Total | Common Shares Issued [Member] | Additional Paid-In Capital [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] |
Beginning balance at Sep. 30, 2015 | $ 165,873 | $ 117,151 | $ 51,052 | $ (2,330) | |
Beginning balance, Shares at Sep. 30, 2015 | 41,838 | ||||
Cash dividends paid | (8,407) | (8,407) | |||
Exercise of stock options | 1,391 | 1,391 | |||
Exercise of stock options, Shares | 91 | ||||
Conversion of restricted stock units | 115 | ||||
Stock compensation expense | 1,611 | 1,611 | |||
Net earnings | 8,893 | 8,893 | |||
Foreign currency translation adjustment | (787) | (787) | |||
Ending balance at Dec. 31, 2015 | $ 168,574 | $ 120,153 | $ 51,538 | $ (3,117) | |
Ending balance, Shares at Dec. 31, 2015 | 42,044 |
Basis of Presentation
Basis of Presentation | 3 Months Ended |
Dec. 31, 2015 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation | 1. Basis of Presentation The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of December 31, 2015, the results of its operations for the three month periods ended December 31, 2015 and 2014, and its cash flows for the three month periods ended December 31, 2015 and 2014. These statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s fiscal 2015 Annual Report on Form 10-K. Financial information as of September 30, 2015 has been derived from the Company’s audited consolidated financial statements. The results of operations for interim periods are not necessarily indicative of the results to be expected for the year. |
Significant Accounting Policies
Significant Accounting Policies | 3 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | 2. Significant Accounting Policies A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 2015 Annual Report on Form 10-K. (a) Recent Accounting Pronouncements In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Condensed Consolidated Financial Statements. (b) Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity. |
Cash and Equivalents
Cash and Equivalents | 3 Months Ended |
Dec. 31, 2015 | |
Cash and Cash Equivalents [Abstract] | |
Cash and Equivalents | 3. Cash and Equivalents Cash and equivalents include the following components: December 31, 2015 September 30, 2015 Cash and Other Cash and Other Overnight repurchase agreements $ 25,147 $ — $ 25,436 $ — Cash on hand— Restricted — 1,000 — 1,000 Unrestricted 28,275 — 24,537 — Total $ 53,422 $ 1,000 $ 49,973 $ 1,000 |
Inventories
Inventories | 3 Months Ended |
Dec. 31, 2015 | |
Inventory Disclosure [Abstract] | |
Inventories | 4. Inventories Inventories are comprised of the following: December 31, September 30, Raw materials $ 7,351 $ 7,095 Work-in-process 12,297 10,096 Finished goods— illumi gene 2,260 1,890 Finished goods—kits and reagents 16,870 16,736 Total $ 38,778 $ 35,817 |
Reportable Segment and Major Cu
Reportable Segment and Major Customers Information | 3 Months Ended |
Dec. 31, 2015 | |
Segment Reporting [Abstract] | |
Reportable Segment and Major Customers Information | 5. Reportable Segment and Major Customers Information Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; and (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Our reportable segments are Diagnostics and Life Science, both of which are headquartered in Cincinnati, Ohio, which also serves as the Diagnostics segment’s base of manufacturing operations and research and development. The Diagnostics segment has sales and distribution facilities in the United States, Europe and Australia. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China to further pursue growing revenue opportunities in Asia. Amounts due from two Diagnostics distributor customers accounted for 26% and 21% of consolidated accounts receivable at December 31, 2015 and September 30, 2015, respectively. Revenues from these two distributor customers accounted for 39% and 41% of the Diagnostics segment third-party revenues during the three months ended December 31, 2015 and 2014, respectively; and represented 29% and 31% of consolidated revenues for the fiscal 2016 and 2015 first quarters, respectively. Within our Life Science segment, two diagnostic manufacturing customers accounted for 18% of the segment’s third-party revenues during each of the three months ended December 31, 2015 and 2014. Segment information for the interim periods is as follows: Diagnostics Life Science Eliminations(1) Total Three Months Ended December 31, 2015 Net revenues— Third-party $ 35,301 $ 11,859 $ — $ 47,160 Inter-segment 71 367 (438 ) — Operating income 10,330 3,236 20 13,586 Goodwill (December 31, 2015) 1,250 20,814 — 22,064 Other intangible assets, net (December 31, 2015) 2,236 3,229 — 5,465 Total assets (December 31, 2015) 120,780 65,927 (272 ) 186,435 Three Months Ended December 31, 2014 Net revenues— Third-party $ 36,586 $ 11,427 $ — $ 48,013 Inter-segment 104 297 (401 ) — Operating income 10,284 2,489 (104 ) 12,669 Goodwill (September 30, 2015) 1,250 21,099 — 22,349 Other intangible assets, net (September 30, 2015) 2,364 3,567 — 5,931 Total assets (September 30, 2015) 119,939 63,670 (327 ) 183,282 (1) Eliminations consist of inter-segment transactions. Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation. |
Intangible Assets
Intangible Assets | 3 Months Ended |
Dec. 31, 2015 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | 6. Intangible Assets A summary of our acquired intangible assets subject to amortization, as of December 31, 2015 and September 30, 2015 is as follows: December 31, 2015 September 30, 2015 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 11,547 $ 10,963 $ 11,582 $ 10,906 Trademarks, licenses and patents 6,349 3,450 6,410 3,296 Customer lists and supply agreements 12,012 10,030 12,105 9,964 $ 29,908 $ 24,443 $ 30,097 $ 24,166 The actual aggregate amortization expense for these intangible assets was $388 and $469 for the three months ended December 31, 2015 and 2014, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2021 is as follows: remainder of fiscal 2016 – $1,009, fiscal 2017 – $1,106, fiscal 2018 – $1,085, fiscal 2019 – $1,045, fiscal 2020 – $873 and fiscal 2021 – $313. |
Significant Accounting Polici14
Significant Accounting Policies (Policies) | 3 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Recent Accounting Pronouncements | (a) Recent Accounting Pronouncements In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes Issued but not yet effective accounting pronouncements are not expected to have a material impact on the Condensed Consolidated Financial Statements. |
Reclassifications | (b) Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity. |
Cash and Equivalents (Tables)
Cash and Equivalents (Tables) | 3 Months Ended |
Dec. 31, 2015 | |
Cash and Cash Equivalents [Abstract] | |
Components of Cash and Cash Equivalents | Cash and equivalents include the following components: December 31, 2015 September 30, 2015 Cash and Other Cash and Other Overnight repurchase agreements $ 25,147 $ — $ 25,436 $ — Cash on hand— Restricted — 1,000 — 1,000 Unrestricted 28,275 — 24,537 — Total $ 53,422 $ 1,000 $ 49,973 $ 1,000 |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Dec. 31, 2015 | |
Inventory Disclosure [Abstract] | |
Components of Inventories | Inventories are comprised of the following: December 31, September 30, Raw materials $ 7,351 $ 7,095 Work-in-process 12,297 10,096 Finished goods— illumi gene 2,260 1,890 Finished goods—kits and reagents 16,870 16,736 Total $ 38,778 $ 35,817 |
Reportable Segment and Major 17
Reportable Segment and Major Customers Information (Tables) | 3 Months Ended |
Dec. 31, 2015 | |
Segment Reporting [Abstract] | |
Segment Information | Segment information for the interim periods is as follows: Diagnostics Life Science Eliminations(1) Total Three Months Ended December 31, 2015 Net revenues— Third-party $ 35,301 $ 11,859 $ — $ 47,160 Inter-segment 71 367 (438 ) — Operating income 10,330 3,236 20 13,586 Goodwill (December 31, 2015) 1,250 20,814 — 22,064 Other intangible assets, net (December 31, 2015) 2,236 3,229 — 5,465 Total assets (December 31, 2015) 120,780 65,927 (272 ) 186,435 Three Months Ended December 31, 2014 Net revenues— Third-party $ 36,586 $ 11,427 $ — $ 48,013 Inter-segment 104 297 (401 ) — Operating income 10,284 2,489 (104 ) 12,669 Goodwill (September 30, 2015) 1,250 21,099 — 22,349 Other intangible assets, net (September 30, 2015) 2,364 3,567 — 5,931 Total assets (September 30, 2015) 119,939 63,670 (327 ) 183,282 (1) Eliminations consist of inter-segment transactions. |
Intangible Assets (Tables)
Intangible Assets (Tables) | 3 Months Ended |
Dec. 31, 2015 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Summary of Acquired Intangible Assets Subject to Amortization | A summary of our acquired intangible assets subject to amortization, as of December 31, 2015 and September 30, 2015 is as follows: December 31, 2015 September 30, 2015 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 11,547 $ 10,963 $ 11,582 $ 10,906 Trademarks, licenses and patents 6,349 3,450 6,410 3,296 Customer lists and supply agreements 12,012 10,030 12,105 9,964 $ 29,908 $ 24,443 $ 30,097 $ 24,166 |
Significant Accounting Polici19
Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Sep. 30, 2015 |
Schedule Of Accounting Policies [Line Items] | ||
Deferred income taxes | $ 4,566 | $ 4,954 |
ASU 2015-17 [Member] | ||
Schedule Of Accounting Policies [Line Items] | ||
Deferred income taxes | $ 3,431 |
Cash and Equivalents - Componen
Cash and Equivalents - Components of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Sep. 30, 2015 | Dec. 31, 2014 | Sep. 30, 2014 |
Cash and Cash Equivalents [Line Items] | ||||
Cash on hand - Restricted | $ 1,000 | $ 1,000 | ||
Total | 53,422 | 49,973 | $ 49,516 | $ 43,047 |
Cash and Equivalents [Member] | ||||
Cash and Cash Equivalents [Line Items] | ||||
Overnight repurchase agreements | 25,147 | 25,436 | ||
Cash on hand - Unrestricted | 28,275 | 24,537 | ||
Total | 53,422 | 49,973 | ||
Other Assets [Member] | ||||
Cash and Cash Equivalents [Line Items] | ||||
Cash on hand - Restricted | 1,000 | 1,000 | ||
Total | $ 1,000 | $ 1,000 |
Inventories - Components of Inv
Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Sep. 30, 2015 |
Inventory [Line Items] | ||
Raw materials | $ 7,351 | $ 7,095 |
Work-in-process | 12,297 | 10,096 |
Total | 38,778 | 35,817 |
Illumigene Instruments [Member] | ||
Inventory [Line Items] | ||
Finished goods | 2,260 | 1,890 |
Kits and Reagents [Member] | ||
Inventory [Line Items] | ||
Finished goods | $ 16,870 | $ 16,736 |
Reportable Segment and Major 22
Reportable Segment and Major Customers Information - Additional Information (Detail) - Customer Concentration Risk [Member] - Customer | 3 Months Ended | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2015 | |
Two Diagnostic Distributor Customers [Member] | Consolidated Accounts Receivable [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Number of major customers | 2 | 2 | |
Concentration risk percentage | 26.00% | 21.00% | |
Two Diagnostic Distributor Customers [Member] | Segment, Third-Party Sales Revenue [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Number of major customers | 2 | 2 | |
Two Diagnostic Distributor Customers [Member] | Segment, Third-Party Sales Revenue [Member] | Diagnostics [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Concentration risk percentage | 39.00% | 41.00% | |
Two Diagnostic Distributor Customers [Member] | Revenues [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Concentration risk percentage | 29.00% | 31.00% | |
Two Diagnostic Manufacturing Customers [Member] | Segment, Third-Party Sales Revenue [Member] | Life Science [Member] | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Number of major customers | 2 | 2 | |
Concentration risk percentage | 18.00% | 18.00% |
Reportable Segment and Major 23
Reportable Segment and Major Customers Information - Segment Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2015 | |
Segment Reporting Information [Line Items] | |||
NET REVENUES | $ 47,160 | $ 48,013 | |
Operating income | 13,586 | 12,669 | |
Goodwill | 22,064 | $ 22,349 | |
Other intangible assets, net | 5,465 | 5,931 | |
Total assets | 186,435 | 183,282 | |
Inter-segment [Member] | Diagnostics [Member] | |||
Segment Reporting Information [Line Items] | |||
NET REVENUES | 71 | 104 | |
Inter-segment [Member] | Life Science [Member] | |||
Segment Reporting Information [Line Items] | |||
NET REVENUES | 367 | 297 | |
Eliminations [Member] | |||
Segment Reporting Information [Line Items] | |||
NET REVENUES | (438) | (401) | |
Operating income | 20 | (104) | |
Total assets | (272) | (327) | |
Operating Segments [Member] | Diagnostics [Member] | |||
Segment Reporting Information [Line Items] | |||
NET REVENUES | 35,301 | 36,586 | |
Operating income | 10,330 | 10,284 | |
Goodwill | 1,250 | 1,250 | |
Other intangible assets, net | 2,236 | 2,364 | |
Total assets | 120,780 | 119,939 | |
Operating Segments [Member] | Life Science [Member] | |||
Segment Reporting Information [Line Items] | |||
NET REVENUES | 11,859 | 11,427 | |
Operating income | 3,236 | $ 2,489 | |
Goodwill | 20,814 | 21,099 | |
Other intangible assets, net | 3,229 | 3,567 | |
Total assets | $ 65,927 | $ 63,670 |
Intangible Assets - Summary of
Intangible Assets - Summary of Acquired Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Sep. 30, 2015 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | $ 29,908 | $ 30,097 |
Accumulated Amortization | 24,443 | 24,166 |
Manufacturing Technologies, Core Products and Cell Lines [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 11,547 | 11,582 |
Accumulated Amortization | 10,963 | 10,906 |
Trademarks, Licenses and Patents [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 6,349 | 6,410 |
Accumulated Amortization | 3,450 | 3,296 |
Customer Lists and Supply Agreements [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 12,012 | 12,105 |
Accumulated Amortization | $ 10,030 | $ 9,964 |
Intangible Assets - Additional
Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Amortization of intangible assets | $ 388 | $ 469 |
Estimated amortization expense for intangible assets remainder of fiscal year 2016 | 1,009 | |
2,017 | 1,106 | |
2,018 | 1,085 | |
2,019 | 1,045 | |
2,020 | 873 | |
2,021 | $ 313 |